IRIDEX Corporation (IRIX) - Total Assets
Based on the latest financial reports, IRIDEX Corporation (IRIX) holds total assets worth $29.15 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check IRIX total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
IRIDEX Corporation - Total Assets Trend (1995–2025)
This chart illustrates how IRIDEX Corporation's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of IRIDEX Corporation to evaluate the quality of earnings relative to operating cash generation.
IRIDEX Corporation - Asset Composition Analysis
Current Asset Composition (December 2025)
IRIDEX Corporation's total assets of $29.15 Million consist of 86.6% current assets and 13.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.7% |
| Accounts Receivable | $9.54 Million | 32.7% |
| Inventory | $7.88 Million | 27.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $984.00K | 3.4% |
| Goodwill | $965.00K | 3.3% |
Asset Composition Trend (1995–2025)
This chart illustrates how IRIDEX Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IRIDEX Corporation market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IRIDEX Corporation's current assets represent 86.6% of total assets in 2025, a decrease from 93.8% in 1995.
- Cash Position: Cash and equivalents constituted 20.7% of total assets in 2025, up from 18.8% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 1995.
- Asset Diversification: The largest asset category is accounts receivable at 32.7% of total assets.
IRIDEX Corporation Competitors by Total Assets
Key competitors of IRIDEX Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
IRIDEX Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.91 | 1.95 | 4.00 |
| Quick Ratio | 1.32 | 1.27 | 3.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.04 Million | $14.18 Million | $32.81 Million |
IRIDEX Corporation - Advanced Valuation Insights
This section examines the relationship between IRIDEX Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 269.77 |
| Latest Market Cap to Assets Ratio | 0.61 |
| Asset Growth Rate (YoY) | 0.1% |
| Total Assets | $29.15 Million |
| Market Capitalization | $17.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values IRIDEX Corporation's assets below their book value (0.61x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: IRIDEX Corporation's assets grew by 0.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for IRIDEX Corporation (1995–2025)
The table below shows the annual total assets of IRIDEX Corporation from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $29.15 Million | +0.05% |
| 2024-12-31 | $29.14 Million | -15.39% |
| 2023-12-31 | $34.44 Million | -18.57% |
| 2022-12-31 | $42.29 Million | -13.14% |
| 2021-12-31 | $48.69 Million | +74.07% |
| 2020-12-31 | $27.97 Million | -19.66% |
| 2019-12-31 | $34.81 Million | -16.46% |
| 2018-12-31 | $41.67 Million | +0.06% |
| 2017-12-31 | $41.65 Million | -13.50% |
| 2016-12-31 | $48.14 Million | +15.11% |
| 2015-12-31 | $41.82 Million | +0.01% |
| 2014-12-31 | $41.82 Million | +24.17% |
| 2013-12-31 | $33.68 Million | +16.48% |
| 2012-12-31 | $28.91 Million | -10.07% |
| 2011-12-31 | $32.15 Million | +10.02% |
| 2010-12-31 | $29.22 Million | +3.28% |
| 2009-12-31 | $28.29 Million | +0.23% |
| 2008-12-31 | $28.23 Million | -39.50% |
| 2007-12-31 | $46.65 Million | +16.12% |
| 2006-12-31 | $40.18 Million | -2.26% |
| 2005-12-31 | $41.10 Million | +5.14% |
| 2004-12-31 | $39.09 Million | +9.08% |
| 2003-12-31 | $35.84 Million | +4.57% |
| 2002-12-31 | $34.27 Million | +1.43% |
| 2001-12-31 | $33.79 Million | -3.53% |
| 2000-12-31 | $35.02 Million | +7.22% |
| 1999-12-31 | $32.66 Million | +15.02% |
| 1998-12-31 | $28.40 Million | +6.37% |
| 1997-12-31 | $26.70 Million | +12.66% |
| 1996-12-31 | $23.70 Million | +270.31% |
| 1995-12-31 | $6.40 Million | -- |
About IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and Oc… Read more